Abbott has launched a “next-generation” delivery system to streamline the electrode implantation process for its Proclaim DRG neurostimulation system.
This advancement aims to improve treatments for individuals with complex regional pain syndrome (CRPS) types 1 and 2, which are known for causing extreme pain.
According to the company, the dorsal root ganglion (DRG) is a nerve cell cluster present along the spine that regulates pain signals from certain regions such as the hip, ankle and foot.
Developed by the company, the Proclaim DRG therapy claims to be the “first and only” DRG technology that gained approval for treating CRPS of the lower limbs.
This system comprises an implantable pulse generator (tiny battery) that generates electrical stimulation.
It also features leads to assist in delivering stimulation to the DRG. Post-implantation, targeted stimulation alleviates the symptoms by “disrupting” pain signals.
Notably, four out of five users of the Proclaim DRG system have experienced pain relief, reducing pain intensity by an average of 81%, stated the company.
The delivery system is said to be crucial for the precise placement of electrodes within the DRG's anatomy.
Its improved manoeuvrability and durability aim to simplify the implant procedure for physicians.
Abbott noted that DRG placement involves using a needle to access the epidural space and guiding the lead to the DRG under image guidance.
Abbott neuromodulation medical director Allen Burton said: "Research shows treating CRPS with targeted DRG neurostimulation results in significantly better outcomes in terms of pain relief and functional improvements than traditional spinal cord stimulation approaches.
"Abbott is continually working to improve DRG technology to better assist physicians in improving patient outcomes. The easier the procedure, the more patients will benefit from it, helping them to live more active, fuller lives with their chronic pain under control."
Last month, the company received FDA approval for an investigational device exemption to assess its coronary intravascular lithotripsy system in a trial.
